Zurich brain injury antibody spinout NovaGo has extended its strategic partnership with immunotherapy company Neurimmune by securing its support in a series A round.
NovaGo Therapeutics, a Switzerland-based developer of therapeutic antibodies for brain injury spun out of University of Zurich, has closed a CHF10m ($10m) series A round co-led by immunotherapy developer Neurimmune.
Neurimmune co-led the round with biopharmaceuticals-focused venture fund Pureos Bioventures.
Founded in 2015, NovaGo Therapeutics is working on antibody candidates to restore neurological function to the brain following cerebral strokes and injuries to the spinal cord.
The antibodies would block an inhibitory factor called Nogo-A shown to…
